HomeCONGRESSInternational Congresses

International Congresses

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Researchers conducted an international, randomized, parallel-group study with a superiority design over a 16-week period. The doses...

ESC 2024 | STOP-or-NOT Trial: Optimal Management of Renin-Angiotensin System Inhibition Before Non-Cardiac Surgery

Researchers conducted a multicenter, randomized study to assess the continuation of renin-angiotensin system inhibition (RASI) before major...

ESC 2024 | AßYSS: Discontinuation of Beta-Blocker Treatment After One Year in Uncomplicated MI

Researchers presented a non-inferiority study conducted at 49 centers in France, with a randomized cohort of stable post-acute...

EuroPCR 2024 | Self-Expanding Valves (ACURATE Neo2) vs. Balloon-Expandable Valves (Sapien 3 Ultra): 1-Year Follow-up Results

Comparing different transcatheter heart valves (THVs) is necessary to obtain relevant information that facilitates the selection of...

EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by...

EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis

Many of the studies comparing TAVR against SAVR in low risk patients included patients between 70-75 years,...

EuroPCR 2024 | CALIPSO: CTO vs Angiography Guided Treatment of Calcified Lesions

The presence of calcified lesions worsens percutaneous coronary intervention prognosis, presenting more restenosis, thrombosis and need for...

EuroPCR 2024 | DOCTORS-LM Trial: CTO Optimizes Stent Outcomes in Left Main Disease?

The aim of this randomized open study was to determine whether CTO guided left main percutaneous coronary...